Benzinga | Nov 12, 2020 04:03PM EST

Navidea Biopharmaceutical Q3 EPS $(0.13) Misses $(0.09) Estimate, Sales $268.00K Beat $150.00K Estimate

Navidea Biopharmaceutical (AMEX:NAVB) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.09) by 44.44 percent. This is a 23.53 percent increase over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $268.00 thousand which beat the analyst consensus estimate of $150.00 thousand by 78.67 percent. This is a 13.17 percent increase over sales of $236.81 thousand the same period last year.